Operetta CLS High-content Imaging System
Operetta CLS High-content Imaging System
批准号:
9274679
负责人:
JOHN S. LAZO
金额:
$51.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-02 至 2018-02-28
关键词:
AutomationBasic ScienceBiologicalBiomedical ResearchCardiovascular DiseasesCellsClinical ResearchCommunicable DiseasesData AnalysesEbola virusEvaluationFluorescence MicroscopyGenesImageIndividualInfluenzaKineticsMalignant NeoplasmsMethodsMutationNerve DegenerationObesityOrganismPeripheralPharmaceutical PreparationsPharmacotherapyPhasePositioning AttributeResearchResearch Project GrantsSamplingSpeedUniversitiesVirginiabasedrug candidatefluorescence imaginghuman diseaseimaging systeminstrumentlight microscopypopulation basedprogramsscreeningtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
High-content screening employs an imaging-based platform, which combines the
efficacy and speed of high-throughput automation and the power of light microscopy,
especially fluorescence microscopy, to simultaneously capture both functional and
morphometric information from a large number of samples of cells or organisms
following perturbation, such as drug treatment or genetic alteration. High content
analysis permits a much more comprehensive quantitative assessment of drug and
gene effects than population-based methods, because multiple kinetic and spatial
readouts can be simultaneously interrogated in individual cells. This application seeks
to fill the gap between a strong demand for high-content screening and the limited
capability the University of Virginia can currently offer. The proposed instrument is a
PerkinElmer Operetta CLS, a high-content imaging system capable of bright-field,
phase-contrast, and wide-field and spinning-disc confocal fluorescence imaging. The
acquisition will immediately benefit a wide range of biomedical research projects
covering infectious diseases such as influenza, Ebola, cardiovascular disease,
obesity, cancer, peripheral and central neurodegeneration. With the Operetta CLS,
multiple parameters can be captured simultaneously for evaluation of tool or drug
candidates against known targets as well as for uncovering unknown new targets in
the exploration of a biological problem. Added benefit is unbiased image acquisition
and powerful data analysis. The Operetta CLS is positioned to critical new research
tool to facilitate our extensive basic or clinical research programs, which are
attempting to understand and find treatments for human diseases.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/psp4.12599
发表时间:
2021-04
期刊:
CPT: pharmacometrics & systems pharmacology
影响因子:
--
作者:
[Zeigler AC, Chandrabhatla AS, Christiansen SL, Nelson AR, Holmes JW, Saucerman JJ]
通讯作者:
Saucerman JJ
Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.
使用合成致死方法缩短确定具有挑战性的肿瘤治疗靶点和药物组合的时间。
DOI:
10.12688/f1000research.13679.1
发表时间:
2018
期刊:
F1000Research
影响因子:
--
作者:
[Lazo,JohnS]
通讯作者:
Lazo,JohnS
DOI:
10.1016/j.slasd.2022.10.002
发表时间:
2023-09
期刊:
SLAS DISCOVERY
影响因子:
3.1
作者:
[Sharlow, Elizabeth R., Llaneza, Danielle C., Grever, William E., Mingledorff, Garnett A., Mendelson, Anna J., Bloom, George S., Lazo, John S.]
通讯作者:
Lazo, John S.
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
-
批准号:10632154
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2022
-
负责人:JOHN S. LAZO
-
依托单位:
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
-
批准号:10330408
-
项目类别:
-
资助金额:$25.22万
-
财政年份:2021
-
负责人:JOHN S. LAZO
-
依托单位:
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
-
批准号:10540550
-
项目类别:
-
资助金额:$5.5万
-
财政年份:2021
-
负责人:JOHN S. LAZO
-
依托单位:
Developing small molecule PTP4A3 inhibitors for ovarian cancer
-
批准号:9769367
-
项目类别:
-
资助金额:$28.93万
-
财政年份:2019
-
负责人:JOHN S. LAZO
-
依托单位:
PTP4A3 as a Molecular Cancer Target
-
批准号:8814295
-
项目类别:
-
资助金额:$20.42万
-
财政年份:2014
-
负责人:JOHN S. LAZO
-
依托单位:
CHEMICAL BIOLOGY FACILITY
-
批准号:8181010
-
项目类别:
-
资助金额:$9.53万
-
财政年份:2010
-
负责人:JOHN S. LAZO
-
依托单位:
siRNA Library Screening for Pharmacologic Radiation Mitigators
-
批准号:8010798
-
项目类别:
-
资助金额:$26.88万
-
财政年份:2010
-
负责人:JOHN S. LAZO
-
依托单位:
Chemical Complementation Assay for MKP-3 (RMI)
-
批准号:7057143
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
In Vitro High Throughput Screening Assay for MKP-3(RMI)
-
批准号:7058166
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Pittsburgh Molecular Libraries Screening Center(RMI)
-
批准号:7076269
-
项目类别:
-
资助金额:$334.7万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Pittsburgh Molecular Libraries Screening Center(RMI)
-
批准号:7691436
-
项目类别:
-
资助金额:$75.75万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Pittsburgh Molecular Libraries Screening Center(RMI)
-
批准号:7231271
-
项目类别:
-
资助金额:$1.99万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
In Vitro High Throughput Screening Assay for MKP-1(RMI)
-
批准号:7058173
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Pittsburgh Molecular Libraries Screening Center(RMI)
-
批准号:7277157
-
项目类别:
-
资助金额:$372.19万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Pittsburgh Molecular Libraries Screening Center(RMI)
-
批准号:7502274
-
项目类别:
-
资助金额:$16.03万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Core--Medicinal chemistry: discovery and screening
-
批准号:7055205
-
项目类别:
-
资助金额:$18.42万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
CANCER STRESS RELEVANT PROTEIN PHOSPHATASE TARGETS
-
批准号:6923496
-
项目类别:
-
资助金额:$14.86万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Chemical Complementation Assay for MKP-1 (RMI)
-
批准号:7058509
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
MOLECULAR PHARM. AND BIOCHEM. OF NOVEL DUAL SPECIIFICITY PHOSPHATASE INHIBITORS
-
批准号:6928832
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
Pittsburgh Molecular Libraries Screening Center(RMI)
-
批准号:6950645
-
项目类别:
-
资助金额:$205.79万
-
财政年份:2005
-
负责人:JOHN S. LAZO
-
依托单位:
海外基金